Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma : a national cohort study in Belgium
Background: Guidelines recommend omalizumab in patients with uncontrolled severe allergic asthma. We investigated real-life use of omalizumab, the proportion of patients fulfilling eligibility criteria, its costs and its effectiveness. Method: In a cohort of asthma patients initiating treatment with omalizumab in Belgium between 2010 and 2016, we investigated fulfilment of eligibility criteria (chronic use of high-dose inhaled corticosteroids (ICSs) plus long-acting beta(2)-agonists (LABAs) and >= 2 severe asthma exacerbations in previous year), and compared hospitalisations and systemic co... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journalarticle |
Erscheinungsdatum: | 2019 |
Schlagwörter: | Medicine and Health Sciences / Chemistry / EXACERBATIONS / THERAPY / PATIENT / DISEASE |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26992082 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://biblio.ugent.be/publication/01GVGB4PM2XYH2DN43HN7YGNE3 |